August 20, 2014 8:47 PM ET

Life Sciences Tools and Services

Company Overview of Second Genome, Inc.

Company Overview

Second Genome, Inc., a life sciences company, develops microbiome-modulating precision therapies. Its microbiome signature discovery services include solutions for microbiome analysis, such as biological specimen storage and sample preparation; sequencing (NGS) and array-based metagenomic assays; and bioinformatics pipelines. Second Genome, Inc. was formerly known as PhyloTech, Inc. and changed its name to Second Genome, Inc. in January 2011. The company was founded in 2009 and is based in San Bruno, California.

1150 Bayhill Drive

Suite 215

San Bruno, CA 94066

United States

Founded in 2009

Phone:

650-440-4606

Key Executives for Second Genome, Inc.

Chief Executive Officer and President
Co-Founder and Chairman of the Board
Age: 57
Co-Founder and Chairperson of Scientific Advisory Board
Co-Founder and Head of Bioinformatics
Senior Vice President of Corporate Development
Age: 50
Compensation as of Fiscal Year 2014.

Second Genome, Inc. Key Developments

Second Genome Enters into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity

Second Genome announced that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders. The worldwide prevalence of obesity and associated metabolic conditions continues to increase rapidly. Emerging evidence suggests that the microbiome is central to metabolic processes. Changes in the composition of gut microbes appear to be linked to metabolic conditions such as obesity and type 2 diabetes. Recent microbiome transplant studies have demonstrated that the introduction of specific microbes can influence host biology to drive weight loss or gain, suggesting the microbiome may be a therapeutic target for obesity treatments.

Second Genome Announces Board Appointments

Second Genome, Inc. announced the appointment of Brad A. Margus, former CEO and co-founder of Envoy Therapeutics, to its board of directors; and Jerrold M. Olefsky, Professor of Medicine at the University of California, San Diego to its scientific advisory board.

Second Genome, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-09-2013 11:45 AM

Second Genome, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-09-2013 11:45 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
Agena Bioscience, Inc. United States
Ricerca Biosciences, LLC United States
Monitoring Force USA, Inc. United States
PRA International Operations, Inc. United States
AllPure Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Second Genome, Inc., please visit www.secondgenome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.